These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
534 related articles for article (PubMed ID: 30738077)
1. Combined locoregional-immunotherapy for liver cancer. Greten TF; Mauda-Havakuk M; Heinrich B; Korangy F; Wood BJ J Hepatol; 2019 May; 70(5):999-1007. PubMed ID: 30738077 [TBL] [Abstract][Full Text] [Related]
2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
3. The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma. Brandi N; Renzulli M Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239941 [TBL] [Abstract][Full Text] [Related]
4. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779 [TBL] [Abstract][Full Text] [Related]
5. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460 [TBL] [Abstract][Full Text] [Related]
6. Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice. Duan X; Wang M; Han X; Ren J; Huang G; Ju S; Zhang Q Cell Cycle; 2020 Dec; 19(24):3595-3607. PubMed ID: 33283623 [TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. Craciun L; de Wind R; Demetter P; Lucidi V; Bohlok A; Michiels S; Bouazza F; Vouche M; Tancredi I; Verset G; Garaud S; Naveaux C; Galdon MG; Gallo KW; Hendlisz A; Derijckere ID; Flamen P; Larsimont D; Donckier V BMC Cancer; 2020 Feb; 20(1):135. PubMed ID: 32075608 [TBL] [Abstract][Full Text] [Related]
8. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Zhao Y; Shuen TWH; Toh TB; Chan XY; Liu M; Tan SY; Fan Y; Yang H; Lyer SG; Bonney GK; Loh E; Chang KTE; Tan TC; Zhai W; Chan JKY; Chow EK; Chee CE; Lee GH; Dan YY; Chow PK; Toh HC; Lim SG; Chen Q Gut; 2018 Oct; 67(10):1845-1854. PubMed ID: 29602780 [TBL] [Abstract][Full Text] [Related]
9. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. Brown ZJ; Hewitt DB; Pawlik TM Expert Opin Investig Drugs; 2022 Apr; 31(4):379-391. PubMed ID: 34788184 [TBL] [Abstract][Full Text] [Related]
10. Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Kim GH; Kim JH; Kim PH; Chu HH; Gwon DI; Ko HK Korean J Radiol; 2021 Nov; 22(11):1822-1833. PubMed ID: 34431250 [TBL] [Abstract][Full Text] [Related]
11. Role of locoregional therapies in the wake of systemic therapy. Palmer DH; Malagari K; Kulik LM J Hepatol; 2020 Feb; 72(2):277-287. PubMed ID: 31954492 [TBL] [Abstract][Full Text] [Related]
14. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494 [TBL] [Abstract][Full Text] [Related]
15. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for hepatocellular carcinoma. Zongyi Y; Xiaowu L Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905 [TBL] [Abstract][Full Text] [Related]
17. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. Roth GS; Decaens T Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036 [TBL] [Abstract][Full Text] [Related]
18. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy. Duan Y; Zhang H; Tan T; Ye W; Yin K; Yu Y; Kang M; Yang J; Liao R Biosci Trends; 2024 Jan; 17(6):427-444. PubMed ID: 37981319 [TBL] [Abstract][Full Text] [Related]
19. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials. Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908 [TBL] [Abstract][Full Text] [Related]
20. Current locoregional therapies and treatment strategies in hepatocellular carcinoma. Cardarelli-Leite L; Hadjivassiliou A; Klass D; Chung J; Ho SGF; Lim HJ; Kim PTW; Mujoomdar A; Liu DM Curr Oncol; 2020 Nov; 27(Suppl 3):S144-S151. PubMed ID: 33343208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]